Drug intelligence / Profile preview

R&D710

Development stage: Preclinical
Lead developer: Bostal Pharma
Modality: Small Molecules
Administration: Intramuscular

Overview

R&D710 is a long-acting injectable (LAI) antipsychotic formulation being developed by Bostal Pharma for the treatment of schizophrenia. Developed via the FDA's 505(b)(2) regulatory pathway, the drug is designed as a six-month (6M) depot injection, which would represent a significant extension in dosing interval compared to many currently available monthly or bimonthly LAIs. By providing sustained therapeutic plasma concentrations over half a year, R&D710 aims to improve long-term medication adherence and reduce the risk of relapse in patients with schizophrenia. The program is currently in early-stage development, with clinical trials projected to begin in 2027.

Other names: R&D710-Bostal-long-acting injectable (LAI)-505(b)(2)-long-acting injectable (LAI)-Schizophrenia

Beyond the preview

Go deeper on R&D710.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on R&D710.

Explore the full profile